Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sipuleucel-T

- PMLiVE

Pfizer expands Xeljanz manufacturing capability in Ireland

Invests $130m in manufacturing in Dublin and Cork

- PMLiVE

Revlimid faces NICE rejection for use in rare blood cancer

Watchdog's draft guidance does not recommend Celgene's drug for NHS use in England and Wales

- PMLiVE

Pfizer wins new European approval for Prevenar 13

Expands use of pneumococcal disease vaccine to cover people aged 18 to 49

- PMLiVE

Interview: David Haslam, NICE

The new chair of the UK’s NICE discusses navigating the stormy waters of health service reforms, collaborating with pharma and the introduction of VBP

- PMLiVE

Novartis and Savient face NICE rejections

Jakavi and Krystexxa turned down for NHS use in England and Wales

National Institute for Health and Care Excellence NICE logo

UK backs use of drugs to prevent breast cancer

Daily use of tamoxifen or raloxifene recommended in at-risk women

- PMLiVE

Cost deters NICE from Sanofi’s bowel cancer drug Zaltrap

Fails to win recommendation despite patient access scheme

- PMLiVE

NICE to support development of HTA in India

UK health standards body will share expertise with India’s Department of Health Research

UK launch for Pfizer’s long-acting contraceptive injection Sayana

Becomes first contraceptive of its kind to reach the UK market

- PMLiVE

NICE knocks back Lilly’s Alimta in new setting

Institute not recommending Lilly’s lung cancer drug for new licence extension

- PMLiVE

Alcon wins initial NICE backing for Jetrea in rare eye condition

Would be first alternative to surgery available to vitreomacular traction patients in England and Wales

Synexus South Africa research sites join Pfizer trial network

CRO's sites become the first in Africa to meet the pharma company's standards

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links